Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.The New England journal of medicine, 355 23
T. Hughes, S. Branford, D. White, J. Reynolds, R. Koelmeyer, J. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, J. Cooney, M. Leahy, P. Rowlings, J. Catalano, M. Hertzberg, R. Filshie, A. Mills, K. Fay, S. Durrant, H. Januszewicz, D. Joske, C. Underhill, S. Dunkley, K. Lynch, A. Grigg (2008)
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.Blood, 112 10
M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, A. Hochhaus, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, J. Radich, B. Simonsson, R. Silver, J. Goldman, R. Hehlmann (2009)
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 35
T. O'hare, W. Shakespeare, Xiaotian Zhu, C. Eide, V. Rivera, Frank Wang, Lauren Adrian, Tianjun Zhou, Wei-sheng Huang, Qihong Xu, C. Metcalf, J. Tyner, M. Loriaux, A. Corbin, Scott Wardwell, Y. Ning, J. Keats, Yihan Wang, R. Sundaramoorthi, Mathew Thomas, Dong Zhou, Joseph Snodgrass, L. Commodore, T. Sawyer, D. Dalgarno, M. Deininger, B. Druker, T. Clackson (2009)
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.Cancer cell, 16 5
J. Cortes, M. Talpaz, D. Bixby, M. Deininger, N. Shah, I. Flinn, M. Mauro, T. O'hare, Simin Hu, R. Kan, V. Rivera, T. Clackson, F. Haluska, H. Kantarjian (2010)
A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response FindingsBlood, 116
D. Yeung, M. Osborn, D. White, S. Branford, Lauren Haswell, C. Slader, S. Issa, D. Hiwase, M. Hertzberg, A. Schwarer, R. Filshie, C. Arthur, Y. Kwan, C. Forsyth, D. Ross, A. Mills, A. Grigg, T. Hughes (2010)
Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II TrialBlood, 116
C. Gambacorti-Passerini, Dong-Wook Kim, H. Kantarjian, T. Brümmendorf, I. Dyagil, L. Griškevičius, H. Malhotra, Y. Goh, Junyuan Wang, K. Gogat, J. Cortes (2010)
An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaBlood, 116
F. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Étienne, J. Reiffers, P. Rousselot (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.The Lancet. Oncology, 11 11
M. Talpaz, J. Cortes, M. Deininger, N. Shah, I. Flinn, M. Mauro, T. O'hare, V. Rivera, H. Kantarjian, F. Haluska (2010)
Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.Journal of Clinical Oncology, 28
H. Kantarjian, N. Shah, A. Hochhaus, J. Cortes, Sandip Shah, M. Ayala, B. Moiraghi, Zhixiang Shen, J. Mayer, R. Pasquini, H. Nakamae, F. Huguet, C. Boqué, C. Chuah, E. Bleickardt, M. Bradley-Garelik, Chao Zhu, T. Szatrowski, D. Shapiro, M. Baccarani (2010)
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.The New England journal of medicine, 362 24
G. Saglio, Dong-Wook Kim, S. Issaragrisil, P. Coutre, G. Étienne, C. Lobo, R. Pasquini, R. Clark, A. Hochhaus, T. Hughes, N. Gallagher, A. Hoenekopp, M. Dong, A. Haque, R. Larson, H. Kantarjian (2010)
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.The New England journal of medicine, 362 24
A. Gratwohl, R. Brand, J. Apperley, C. Crawley, T. Ruutu, P. Corradini, E. Carreras, A. Devergie, C. Guglielmi, H. Kolb, D. Niederwieser (2006)
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).Haematologica, 91 4
R. Hehlmann, Susanne Jung-Munkwitz, M. Lauseker, Martin Müller, Armin Leitner, Nadine Pletsch, Ulrike Proetel, A. Gratwohl, G. Ehninger, D. Hossfeld, C. Nerl, H. Pralle, Dominik Heim, Gabriela Baerlocher, L. Balleisen, H. Einsele, C. Falge, A. Ho, Matthias Hänel, M. Pfreundschuh, L. Kanz, F. Stegelmann, C. Köhne, Stephan Kremers, Karsten Spiekermann, Steffen Koschmieder, C. Waller, M. Bentz, S. Krause, Benjamin Hanfstein, Susanne Schnittger, Markus Pfirrmann, J. Hasford, Andreas Hochhaus, S. Saussele (2010)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011, pp 185-234Oncology Research and Treatment, 34
Chronic myeloid leukaemia (CML) is a paradigmatic disease, as knowledge on the molecular pathology of CML has driven the development of targeted drugs, which finally led to a substantial improvement of the patients' prognosis. However, despite very potent drugs, such as Imatinib, Nilotinib and Dasatinib for first- and second-line therapy are available, there is still place for improvement. Especially, selection of highly resistant T315I mutated clones represents a relevant clinical problem. The highlight of the 52nd Annual Meeting of the American Society (ASH) in 2010 for CML patients was data marking a profound step forward for patients developing a T315I mutation by providing safety and first efficacy results from a clinical trial testing Ponatinib, a TKI targeting T315I-mutated CML. These very early results from a small patient cohort provide a rationale basis for prospective testing of the drug in T315I-mutated CML and will help to further complement the "TKI cocktail" now available for CML patients.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jun 30, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.